Since its founding in 1941, Southern Research has participated in the development of approximately half of all FDA-approved anticancer drugs. Our cancer therapeutics professionals evaluate hundreds of compounds yearly to establish their in vitro and/or in vivo efficacy potential. This experience enables us to design optimal studies that provide critical preclinical anticancer efficacy data for our clients’ drug development programs.

Services

Contact Us

As a full-service nonclinical CRO, Southern Research offers clients a full continuum of drug development services. By providing histopathology, clinical pathology, and bioanalytical services in-house, Southern Research more efficiently moves a client’s drug down the development pipeline to IND submission. An in vitro efficacy program can quickly move to in vivo efficacy. Once efficacy has been established and optimized, a program can seamlessly transition to safety assessment in our Preclinical Toxicology Department.

 

Now seeking partners for Transgenic Mouse Human PD-1/L1 Model

We are currently seeking a limited number of partners willing to allow us to incorporate data from their study run here at Southern Research as part of our continuing model characterization in order to evaluate checkpoint inhibitors either alone or in combination with other immune modulating agents, chemotherapeutics, oncolytic viruses, or radiation. Selected partners will get a significantly reduced rate for their study in exchange for data access.

Click here to learn more.

 

  • In Vitro
    • Proliferation
    • Cytotoxicity
    • 3D Tumor spheroid
    • Microfluidic tumor model
    • Colony formation
    • Mechanism of action (MOA)
    • Invasion/migration
    • Apoptosis
    • Cell cycle
    • Angiogenesis
    • Receptor binding
    • Combination (drug-drug and drug radiation)
    • Combination sequencing & scheduling
    • Consulting services
    • Custom model development
  • In Vivo
  • Consulting

    Southern Research Oncology Scientists average over 15 years of cancer therapeutic development experience. We offer our clients access to these years of knowledge through our Consulting Services.

    We can provide consulting from Chemistry though Lead Identification/Optimization, Safety Assessment, Compound Scale-up, and Production.

     

  • Key Capabilities

    Southern Research provides access to a broad range of capabilities that allow for the establishment of custom research programs.

    • Label-free, real-time analysis (xCELLigence)
    • Flow cytometry, including FACS
    • Magnetic cell enrichment
    • High-content imaging
    • Confocal microscopy
    • High throughput screening (HTS)
    • In vitro/In vivo irradiator
    • Biolayer interferometry (Octet assay system)
    • BSL-2 in vitro & in vivo labs
    • Large vivarium capacity
    • Transgenic breeding colony
    • Molecular biology
    • Immunology
    • Histopathology
    • Clinical pathology
    • Bioanalytical services
    • qPCR
    • Oncology Consulting services including
      • Chemistry
      • Lead identification
      • Lead optimization
      • Safety assessment
      • Compound scale-up
      • Production

Solutions

Contact Us

Southern Research offers a customized approach to oncology therapeutic development. We are experienced in evaluating chemotherapeutic agents, antibody therapeutics, oncolytic viruses, prophylactic and therapeutic vaccines, and radiation sensitizers. Our newest service offerings are in support of immuno-oncology (IO) therapeutic development and include classic syngeneic mouse tumor models and several Genetically Engineered Mouse Models (GEMMs) expressing the human form of PD-1/L1 or CTLA-4. The GEM models allow for evaluation of the fully human-form of checkpoint inhibitors either alone or in combination with other immune modulating agents, chemotherapeutics, oncolytic viruses, or radiation.

  • Small Molecule Development

    For over 60 years Southern Research has played a key role in development of many of the small molecule cancer therapeutics that have saved or prolonged patient lives. Southern Research stands ready to apply our experience gained from assisting in the development of nearly half of all the approved small molecule cancer therapeutics to your small molecule cancer therapeutic program.

    • Services
      • Chemistry (consulting)
      • High Throughput Screening
      • In vitro efficacy
      • Mechanism of action
      • Syngeneic & Xenograft models
      • Radiation sensitization
      • Combination sequencing and scheduling
      • Pharmacokinetics
      • Biodistribution
      • IND-enabling toxicology
    • Staff resources
      • Chemists
      • Cancer biologists
      • Cell & molecular biologists
      • Radiation biologist
      • Pathologists
      • Toxicologists
    • Support services
      • Chemistry
      • Histopathology
      • Clinical Pathology
      • Bioanalytical
  • Immuno-Oncology Development

    With a characterized human PD-1/L1 double knock-in transgenic mouse model available for checkpoint and chemotherapy/checkpoint combination evaluation, and two transgenic CTLA-4 models under development, Southern Research’s newest services are focused on providing the support required for the immuno-oncology community.

    • Services
      • In vitro efficacy
      • Combination sequencing and scheduling
      • Syngeneic mouse models
      • Transgenic mouse models
      • Immune characterization
      • Flow cytometry, including FACS
      • Multiplex immunoassays, cytokine panels
      • Immunogenicity
      • Pharmacokinetics
      • Biodistribution
      • IND-enabling toxicology
    • Tumor Model Systems
      • Syngeneic Mouse Models
        • MC38, CT26.WT, Colon 26, EMT-6, B16/F10, PAN02, Lewis Lung, RENCA, TC-1 (HPV+)
      • Transgenic Mouse Models
      • C57BL/6 (Efficacy models)
        • Human PD-1/PD-L1 Double KI/KO
        • Human CTLA-4 KI/KO
      • BALB/c (Toxicology model)
        • Human CTLA-4 KI/KO
    • Staff resources
      • Cancer biologists
      • Immunologists
      • Pathologists
      • Toxicologists
    • Support services
      • Histopathology
      • Clinical Pathology
      • Immunology
      • Bioanalytical
  • Oncolytic Virus Development

    Southern Research ran our first oncolytic virus study in 2006.  Since those early days, we have continued to evolve services to be able to provide a coordinated package of virology, immunology, tumor biology, and toxicology services to support even the most ambitious oncolytic virus development program.

    • Virus types
      • Adenoviruses
      • Adeno-Associated Viruses
      • Enteroviruses
      • Herpes Simplex Virus
      • Lentivirus
      • Measles Virus
      • Newcastle Disease Virus
      • Vaccinia Virus
      • Vesicular Stomatitis Virus
      • Others, as needed
    • Services
      • In vitro and in vivo efficacy
      • Plaque assay for dose confirmation and biodistribution
      • qPCR for biodistribution and transgene expression analysis
      • Immune characterization
      • Flow cytometry
      • Multiplexed immunoassays
      • Immunogenicity
      • IND-enabling toxicology
      • Neurovirulence and neuropathology
      • Clinical trial sample analysis
    • Staff resources
      • Cancer biologists
      • Virologists
      • Immunologists
      • Pathologists
      • Toxicologists
    • Support services
      • Immunology
      • Histopathology
      • Clinical Pathology
      • Bioanalytical
  • Cancer Vaccine Development

    Prophylactic, therapeutic, antigen, DNA, and RNA, Southern Research is experienced in working with all cancer vaccine platforms.

    • Services
      • In vivo efficacy
      • Immune characterization
        • Flow cytometry
        • Multiplexed immunoassays
        • Immunogenicity
      • IND-enabling toxicology
      • Biomarkers
      • Clinical trial sample analysis
    • Staff Resources
      • Cancer biologists
      • Immunologists
      • Pathologists
      • Toxicologists
    • Support services
      •  Immunology
      • Histopathology
      • Clinical Pathology
      • Bioanalytical

Meet Our Researchers

Michael Koratich | Associate Director, Head of Oncology

Michael Koratich is Associate Director and Head of Oncology in Southern Research’s Drug Development Division. Throughout his 18-year career at Southern Research, he has focused on supplying the pharmaceutical and biotechnology sectors research and development approaches to help drive their cancer therapeutic programs forward. His group is currently focused on establishing and characterizing models for use in the development of immuno-oncology therapeutics, while maintaining the expertise in small molecule cancer therapeutics for which Southern Research is noted. During his time at Southern Research, he has participated in more than a thousand studies and has played a part in the approval of eight therapeutics. Prior to joining Southern Research, Michael served for eight years in the US Army at the Army Research of Environmental Medicine in Natick, MA. During this time he explored cellular responses to heat stress and possible connections between gut microbiome and the pathophysiology of heat stroke. He received his B.S. and M.S. in Biology with a concentration in microbiology from California University of Pennsylvania in 1989 and 1991, respectively.

Murray Stackhouse, Ph.D. | Senior Scientist

As senior scientist in Cancer Therapeutics and Immunology, Murray Stackhouse serves as study director for all in vivo cancer studies at Southern Research. His current research involves the use of xenograft models to screen anti-cancer therapies alone or in combination with other compounds or radiation. His other area of interest involves the use of syngeneic mouse models for the investigation of new immune-oncology therapeutics. Stackhouse has over 15 years of experience in the design, conduct, and interpretation of in vivo studies with human tumor xenografts, as well as murine tumors. Before joining Southern Research in 2002 as a study director, Stackhouse was an assistant professor in the Radiation Oncology Department at the University of Alabama at Birmingham. He is a professional member of the American Association of Cancer Research. He has co-authored 29 publications and 30 abstracts. He earned his doctorate in radiation biology from Colorado State University and completed his postdoctoral work at Los Alamos National Laboratory. Stackhouse earned his Bachelor of Arts in microbiology from Weber State University.